The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicity. (Q54336738)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25040563%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

title

The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicity (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25040563%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25040563%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Vijay Suppiah

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25040563%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

David Foster

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25040563%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Richard N Upton

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25040563%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Michael D Wiese

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25040563%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

C E O'Doherty

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25040563%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

L D Spargo

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25040563%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

L G Cleland

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25040563%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

S M Proudman

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25040563%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

publication date

8 July 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25040563%20AND%20SRC:MED&resulttype=core&format=json

Journal of Clinical Pharmacy and Therapeutics

10 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25040563%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25040563%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25040563%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

555-560

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25040563%20AND%20SRC:MED&resulttype=core&format=json

Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients

10 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12189

Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12189

Recent advances in the genetics of RA susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12189

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12189

HLA-DRB1 typing in rheumatoid arthritis: predicting response to specific treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12189

Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12189

Immunology: Csk keeps LYP on a leash.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12189

Investigation of genetic variation across the protein tyrosine phosphatase gene in patients with rheumatoid arthritis in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12189

A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12189

PTPN22 1858C>T polymorphism is strongly associated with rheumatoid arthritis but not with a response to methotrexate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12189

Genetics of autoimmune diseases--disorders of immune homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12189

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12189

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12189

Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12189

When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12189

Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12189

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12189

Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12189

The rheumatoid arthritis HLA-DRB1 shared epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12189

New therapies for treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12189

Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12189

A method for estimating the probability of adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12189

Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12189

Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12189

PTPN22 alters the development of regulatory T cells in the thymus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12189

Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12189

Requirement for diverse TCR specificities determines regulatory T cell activity in a mouse model of autoimmune arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12189

TNF downmodulates the function of human CD4+CD25hi T-regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12189

Association of the PTPN22 C1858T single-nucleotide polymorphism with rheumatoid arthritis phenotypes in an inception cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12189

The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12189